SAG
BMRN icon

SageView Advisory Group’s BioMarin Pharmaceuticals BMRN Stock Holding History

SageView Advisory Group’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-598
Closed -$35.5K – 822
2025
Q4 		$35.5K Buy
+598
New +$32.6K ﹤0.01% 1213
2024
Q1 		– Sell
-2,945
Closed -$264K – 540
2023
Q4 		$264K Buy
+2,945
New +$261K 0.01% 548

Other funds holding BMRN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

SageView Advisory Group's BMRN Position: Q1 2026 in Review

SageView Advisory Group sold out of BioMarin Pharmaceuticals (BMRN) in Q1 2026, closing a stake of 598 shares — an estimated $35.5K sold.

SageView Advisory Group first reported a position in BMRN in Q4 2023 and held it in 2 quarters. The position peaked at $264K in Q4 2023. 559 funds tracked by Wall St. Rank hold BMRN as of Q1 2026.

  • SageView Advisory Group reported no remaining BioMarin Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • SageView Advisory Group sold 598 BioMarin Pharmaceuticals shares in Q1 2026, an estimated $35.5K.
  • SageView Advisory Group first reported a position in BioMarin Pharmaceuticals in Q4 2023 and held it in 2 quarters.
  • SageView Advisory Group's BioMarin Pharmaceuticals position peaked at $264K in Q4 2023.
  • 559 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q1 2026.

Based on SageView Advisory Group's 13F filing for Q1 2026, filed 10 Aug 2026.